Search Results for "Oncology Strategy Pfizer"
Original Source: Pfizer Oncology
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including breast, lung, prostate, sarcoma, melanoma, and various hematologic cancers. Pfizer Oncology has biologics and...
Matching Channels
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...
Matching News
VLST expands into oncology with clinical-stage Pfizer antibody
The private US biotechnology firm VLST has added oncology to its list of targeted disease areas, on top of autoimmune and inflammatory disorders, by in-licensing the anti-CD40 monoclonal antibody CP-8...
Pfizer's Long Term Strategy: A Possible Breakup
By Peter Geschek:Pfizer (PFE), the world's largest drugmaker, may consider dividing its branded medicines and generic product units into separate businesses, CEO Ian Read said recently.This is part of...
Pfizer's Long-Term Strategy: A Possible Breakup
By Peter Geschek:Pfizer (PFE), the world's largest drugmaker, may consider dividing its branded medicines and generic product units into separate businesses, CEO Ian Read said recently.This is part of...
Pfizer recognises the importance of biotechnology and the need for good science. Barbara Dalton and Daniel Grant explain their different roles in Pfizer and the ways in which the company can invest to...
Pfizer’s Out-licensing Opportunities
In 2008 Pfizer refined their R&D strategy and decided to decrease the number of therapeutic areas that their teams were focusing on. The result of this decision is that the company now has approximate...
CytomX partners with Pfizer to develop Probody drug conjugates in oncology
Biotechnology company CytomX Therapeutics has signed a strategic agreement with Pfizer for the development and commercialisation of multiple Probody drug conjugates (PDCs) in the field of oncology.
Pfizer: An Ideal Development Partner
In this episode of PharmaTelevision News Review, Paul Larsmon talks with Doug Giordano, Vice President, Business Development at Pfizer. Filmed at BIO-Europe 2009, they discuss: • the strategy behind...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the G...
Matching PubMed Articles
An in situ oxidation strategy towards overcoming hERG affinity.
In an effort to overcome hERG affinity with a lead compound, several S-oxide and N-oxide analogues were synthesised with a much improved hERG profile but low in vivo absorption. This led to the implem...
Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Causal reasoning on biological networks: interpreting transcriptional changes.
The interpretation of high-throughput datasets has remained one of the central challenges of computational biology over the past decade. Furthermore, as the amount of biological knowledge increases, i...
